Journal of natural medicinesHumansAldo-Keto Reductase Family 1 Member C3MaleProstatic NeoplasmsCastration-Resistant
Casticin inhibits AKR1C3 and enhances abiraterone efficacy in castration-resistant prostate cancer.
Kamil Piska, Michał Zubek, Adam Bucki, Maria Świtalska, Paulina Koczurkiewicz-Adamczyk, Benedykt Władyka, Marcin Kołaczkowski, Elżbieta Pękala
Published: 202610.1007/s11418-025-01974-8
Abstract
Castration-resistant prostate cancer (CRPC) continues to represent a critical therapeutic hurdle owing to its resistance to both androgen deprivation and next-generation antiandrogens like abiraterone (ABI). One of the key mechanisms underlying this…
Preview only. Read the full abstract at the source